In most mid-size pharmaceutical manufacturing operations, a single batch record review cycle consumes between two and four working days. Ask a quality director where that time goes and you will hear roughly the same answer: the reviewers are spending most of it on preparation, not decision-making. Pulling together supporting documents, cross-referencing against the master batch record, checking completeness, sorting exceptions by type and severity, and routing packages to the right people. By the time a qualified reviewer is actually making quality judgments, a large portion of the review window has already passed.
This is the specific problem that batch record review automation is designed to address. Not the review itself, which requires human expertise, product knowledge, and regulatory accountability. The preparation that precedes it.
Where the time actually goes
A detailed breakdown of manual batch record review typically shows four discrete work categories. The first is document assembly: identifying which documents belong to a given batch, locating them across systems (the EBR, the LIMS, environmental monitoring logs, equipment usage records), and confirming their completeness. In a well-organized operation this might take thirty minutes per batch. In a less organized one it can take two to three hours.
The second category is specification cross-referencing: comparing actual recorded values against the limits and ranges defined in the master batch record. For a solid-dose batch with forty or fifty in-process checks, this is systematic but not trivial. The third is exception documentation: capturing what is out-of-spec, incomplete, or requires supplemental explanation, and structuring it in a form the reviewer can act on. The fourth is routing and prioritization: deciding who needs to see what, in what order, and what constitutes an exception that might delay release.
The judgment-dependent portion of the work, the part that requires a qualified person with product knowledge to make regulatory-accountable decisions, is narrower than most people assume when they look at calendar time. Calendar time includes waiting, handoffs, and repeated context-switching by reviewers who handle multiple batches in parallel.
What AI-assisted intake actually does
An automated batch record review system reads the structured and semi-structured data from completed batch documentation, applies the specification limits defined in the master batch record, identifies fields that are outside limits or have missing values, and generates a structured exception summary organized by type and severity. It also logs every step it takes in an audit-trail-compatible format, because every action in a system that touches release decisions needs to be traceable under 21 CFR Part 11.
The system is not determining whether a batch should be released. That decision requires a qualified reviewer to evaluate the exceptions in context, consider manufacturing history, assess the materiality of deviations, and sign off with the accountability that comes with their role. What the system does is eliminate the preparation work so the reviewer arrives at that decision with a complete, organized package instead of spending their first ninety minutes assembling one.
What early-access pilot data shows
In early-access work with four manufacturing sites, the preparation phase of batch record review, which typically runs sixty to one hundred twenty minutes per batch in a manual process, has been reduced to approximately ten to twenty minutes with automated intake and exception flagging. The review and disposition phase, where qualified reviewers evaluate exceptions and make release decisions, stays roughly constant in elapsed time but becomes more focused because the context is better organized and the exception list is more consistent across reviewers.
One site processing small-molecule oral solid doses found that review packages assembled by the automated system had a materially lower rate of supplemental documentation requests than manual packages. The interpretation we take from that is not that the AI is finding more exceptions, but that it is finding them more consistently. Manual preparation has natural variability across reviewers and time-of-day effects. Automated intake applies the same rules the same way every time.
We are careful not to overstate these numbers. They come from four pilot sites under controlled conditions with an engineering team present. The results will differ by operation, by product type, and by how well the existing batch record system is structured to begin with.
The validation requirement
Any software system operating in a GMP environment and touching data that affects release decisions is subject to validation requirements under 21 CFR Part 11 and applicable GMP regulations. This is not optional and it is not a technicality. It is the foundational requirement that makes automated outputs trustworthy enough to act on.
The practical question is not whether to validate, but how much of the validation burden falls on the quality team versus what the vendor provides. A software system designed for regulated environments should come with Installation Qualification, Operational Qualification, and Performance Qualification documentation, a Validation Master Plan, risk assessments, and the traceability matrix linking system requirements to test cases. A vendor who cannot provide these at contract signature has not built a system intended for pharmaceutical manufacturing.
Validation engagement timelines for a purpose-built regulated-environment system typically run six to ten weeks from kick-off to final report, assuming the customer's quality team is resourced to participate in OQ and PQ execution. Multi-year validation timelines are a signal that the system was not designed with regulated environments in mind, not that the regulatory requirements are uniquely demanding.
What does not change
Automation does not change who has accountability for quality decisions. The qualified reviewer who signs off on a batch disposition is responsible for that disposition regardless of how the review package was assembled. Automation does not change what constitutes a valid electronic signature under 21 CFR 11.100 and 11.200. It does not change the requirement for complete, unalterable audit trail coverage of every system action that affects a record. It does not change the need for change control when modifying the system after validation.
What it changes is the ratio of preparation time to decision time, and the consistency with which exceptions are identified and classified. For operations where qualified reviewer time is the binding constraint on batch release throughput, improving that ratio has direct capacity implications. For operations where the main concern is inspection readiness, improved consistency in how exceptions are captured and documented has direct implications for the quality of the CAPA record and the defensibility of the release decision history.
Choosing the right scope
We are not arguing that every pharma operation should automate batch record review, or that the value case is identical across product types and regulatory contexts. Biologic manufacturers with complex in-process monitoring profiles face different documentation structures than solid-dose generics manufacturers. Contract manufacturing organizations handling multiple customer master batch records in parallel face different routing complexity than captive manufacturers. The right scope for automation depends on where the preparation burden actually sits in your specific operation.
The question worth asking before evaluating any system is: what fraction of our batch record review cycle is preparation versus judgment, and where is the preparation time going? If the answer reveals that qualified reviewer time is being spent on work that does not require their expertise, automation has a clear and defensible role. If the answer reveals that the bottleneck is actually at the judgment stage, which can happen in operations with high deviation rates or complex exception profiles, automation of the preparation phase will have limited impact on throughput and the underlying quality issue needs to be addressed separately.
See how Katalyze AI performs on your documentation
Talk to the team about your batch records and deviation history. We will show you a working demo configured to your product type.
Request a Demo
